Form 4 for HUMA Humacyte, Inc.
Accepted 2021-08-27 00:00:00 ET · period of report 2021-08-26 · accession 0001104659-21-110531 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2021-08-27 | 2021-08-26 | HUMA | Wallace Max N. | Dir | A - Grant | — | +50.0K | 50.0K | New | — |
| DM | 2021-08-27 | 2021-08-26 | HUMA | Wallace Max N. | Dir | A - Grant | — | +36.8K | 17.1K | New | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-08-26 | A | A | 49,986 | — | 49,986 | D | — | — | (F1) On August 26, 2021, Alpha Healthcare Acquisition Corp. ("AHAC") consummated a business combination (the "Business Combination") by and among AHAC, Hunter Merger Sub, Inc., a Delaware corporation ("Hunter Merger Sub") and Humacyte, Inc., a Delaware corporation ("Legacy Humacyte"), AHAC changed its name to "Humacyte, Inc." and Hunter Merger Sub merged with and into Legacy Humacyte. As part of the Business Combination, each share of Legacy Humacyte stock was exchanged for 0.2626 shares of common stock of Humacyte, Inc. |
| 2 | Derivative | Stock Options (right to buy) | 2021-08-26 | A | A | 6,564 | — | 6,564 | D | $1.19 · — to 2023-11-22 | 6,564 Common Stock | (F3) As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc. (F2) Options are fully vested and exercisable. |
| 3 | Derivative | Stock Options (right to buy) | 2021-08-26 | A | A | 13,129 | — | 13,129 | D | $2.56 · — to 2025-09-01 | 13,129 Common Stock | (F3) As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc. (F2) Options are fully vested and exercisable. |
| 4 | Derivative | Stock Options (right to buy) | 2021-08-26 | A | A | 17,068 | — | 17,068 | D | $6.54 · — to 2028-04-12 | 17,068 Common Stock | (F3) As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc. (F2) Options are fully vested and exercisable. |